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Objectives The purpose of this study was to determine whether spironolactone use is associated with fractures in men with
congestive heart failure (CHF).
Background In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of
spironolactone to fractures is not known.
Methods The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical
Center, Memphis, Tennessee, were reviewed (n  4,735). Odds ratios with 95% confidence intervals of having a
fracture associated with spironolactone use were estimated using conditional logistic regression.
Results We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control sub-
jects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total
fracture (odds ratio: 0.575; 95% confidence interval: 0.346 to 0.955, p  0.0324).
Conclusions The use of spironolactone is inversely associated with fractures in men with CHF. (J Am Coll Cardiol 2008;52:
135–8) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.039(
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bongestive heart failure (CHF) has its origins rooted in a
alt-avid state mediated by neurohormonal activation that
ncludes effector hormones of the renin-angiotensin-
ldosterone system (RAAS) (1). Observational studies have
uggested an interrelationship between CHF and osteopo-
osis (2–4). Spironolactone, an aldosterone receptor antag-
nist, preserves skeletal health in rats with aldosteronism
5). However, the relationship between spironolactone use
nd fracture risk in humans is controversial (6,7). In this
tudy, we explored the association between spironolactone
se and fractures.
ethods
ase and control definitions. After approval from the
eterans Affairs Medical Center (VAMC), Memphis, Ten-
essee, Institutional Review Board, the medical records
rom the *Department of Veterans Affairs Medical Center, †Department of Medi-
ine, and ‡Department of Preventive Medicine, University of Tennessee Health
cience Center, Memphis, Tennessee.t
Manuscript received December 5, 2007; revised manuscript received February 15,
008, accepted March 4, 2008.including pharmacy data and radiographs) of all male
eterans hospitalized at this VAMC from January 1999 to
uly 2005 with an International Classification for Diseases–
th edition (ICD-9) code consistent with CHF were
eviewed (n  4,735). A fracture case was defined as any
ale veteran with a history of CHF and a nontraumatic
racture between 1999 and 2005. Cases with a medical
isorder associated with bone metabolism were excluded.
onfracture control subjects (same exclusions as cases) were
en with CHF with no history of a nontraumatic fracture
etween these dates. We defined nontraumatic fractures as
hose that occurred with no identifiable trauma or from a
all from less than a standing height (8). A total of 1,655
atients met at least 1 exclusion criteria and were excluded;
89 cases, including 167 with single fractures and 668
ontrol subjects selected at random and matched to cases
ased on age (1 year) and race in a 4:1 control/case ratio,
ere included.
emographic factors and medications. Age; race; height;
eight; cigarette use; prevalent fractures of the hip, verte-
rae, and wrist; and exposure to beta-blockers, loop and
hiazide diuretics, angiotensin-converting enzyme inhibi-
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Fracture Risk in Men With CHF July 8, 2008:135–8tors, angiotensin receptor blockers,
anticonvulsants, corticosteroids,
bisphosphonates, and teriparatide
between 1999 and 2005 were re-
corded. For control subjects, any
use of these medications between
January 1999 and July 2005 was
considered use; for cases, use was
between these dates and before
the incident fractures. The dura-
ion and highest dose of spironolactone used before the
ndex date of the fracture (cases) or between 1999 and 2005
control subjects) were recorded.
racture history. Incident fractures between 1999 and
005 were included except those related to trauma or to
kull, facial, or rib fractures. We included a vertebral fracture
f there was a fracture on radiographs between 1999 and
005 and a radiograph before these dates without a vertebral
racture or a notation that this was an incident fracture.
owever, for some vertebral fractures, we could not ascer-
ain whether the fracture was incident. This occurred
ecause there was a fracture present on a radiograph
etween 1999 and 2005 with no prior radiographs and no
linical record of the fracture. Vertebral fractures are impor-
ant (9); therefore, in our statistical analysis, we ran 2
tatistical models for total fractures, 1 including and 1
xcluding vertebral fractures.
tatistical analysis. Differences in baseline characteristics
nd medication use in cases and control subjects (Tables 1
nd 2) were determined using t tests for continuous variables
nd chi-square testing for categorical variables. Conditional
ogistic regression was used to determine odds ratios (ORs)
or patients with fractures. Models were adjusted for smok-
ng status, body mass index, prevalent fractures, and other
edication exposures that may be associated with bone
etabolism. The ORs with 95% confidence intervals (CIs)
nadjusted and adjusted for these variables are presented.
uration of exposure (6 and 6 months) to spironolac-
one was entered into the model.
Abbreviations
and Acronyms
CHF  congestive heart
failure
CI  confidence interval
OR  odds ratio
RAAS  renin-angiotensin-
aldosterone system
elected Characteristics of the Study Population
Table 1 Selected Characteristics of the Study Population
Characteristic
Cases
(n  167)*
Control Subjects
(n  668)* p Value
Age (yrs)† 67.74 (10.52) 67.74 (10.39) 0.8186
Race†
White 74.25% 73.95% 0.9251
Black 20.36% 21.26% 0.8724
Unknown 5.39% 4.79% 0.9113
Body mass index (kg/m2) 28.37 (7.52) 29.16 (14.29) 0.5313
Smoking status
Never 16.77% 19.46% 0.5143
Current 38.32% 32.19% 0.1634
Past 39.52% 38.77% 0.8650
Not known 5.39% 9.58% 0.0897(
alues given are mean (SD) or percent. *For body mass index: cases n  163, control subjects
 631. †Matching variable.In our analyses, we included a total of 167 cases with
ingle fractures. In a separate analysis of multiple-fracture
ases, we included 21 cases age- and race-matched to 84
ontrol subjects and determined crude and adjusted ORs for
otal fractures.
All analyses were performed using SAS version 9.1 (SAS
nstitute Inc., Cary, North Carolina). The p values were
-sided and were considered statistically significant if p 0.05.
esults
ables 1 and 2 depict clinical characteristics and medication
se in the study population. In unadjusted and adjusted
odels, use of spironolactone was inversely associated with
otal fractures, OR: 0.480 (95% CI: 0.308 to 0.749), p 
.0012, and OR: 0.575 (95% CI: 0.346 to 0.955), p 
.0324, respectively (Table 3). Exclusion of vertebral frac-
ures from the total fracture analysis did not significantly
hange the results (data not shown). Analysis of the multi-
le fracture data also revealed a significant crude and
djusted inverse association of spironolactone use with total
ractures, OR: 0.120 (95% CI: 0.015 to 0.938), p  0.0433,
nd OR: 0.092 (95% CI: 0.009 to 0.964), p  0.0465.
here was no significant association of spironolactone use
ith hip (or site of hip), wrist, or vertebral fractures (Table
). However, in both unadjusted models, OR: 0.381 (95%
I: 0.162 to 0.897), p  0.0272, and adjusted models, OR:
.236 (95% CI: 0.077 to 0.726), p  0.0118, use of
pironolactone was inversely associated with the category of
ther fractures (Table 3). In unadjusted models, there was a
ignificant inverse association of spironolactone use with
onvertebral fractures, OR: 0.508 (95% CI: 0.289 to 0.894),
 0.0189, with a trend after adjustment for covariates,
R: 0.550 (95% CI: 0.286 to 1.058), p  0.0733.
There were too few users of doses of spironolactone 25
g/day to determine the association between dose of
pironolactone and fractures. In adjusted models, long-term
edication Use in Study Population
Table 2 Medication Use in Study Population
Characteristic
Cases
(n  167)
Control
Subjects
(n  668) p Value
Cardiac medications
Beta-blocker 55.42% 65.87% 0.0122
Loop diuretic 77.11% 82.49% 0.1110
Thiazide diuretic 24.39% 32.23% 0.0510
Angiotensin-converting
enzyme
68.07% 78.89% 0.0031
Angiotensin receptor blocker 10.24% 9.60% 0.8016
Osteoporosis medications
Bisphosphonates 6.06% 1.35% 0.0013
Teriparatide 0% 0.15% 1.0000
Other medications
Corticosteroids 22.42% 14.97% 0.0207
Anticonvulsants 16.87% 13.62% 0.28476 months) exposure to spironolactone was inversely
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July 8, 2008:135–8 Fracture Risk in Men With CHFssociated with total fractures, OR: 0.555 (95% CI: 0.313 to
.981), p  0.0428 (Table 4).
iscussion
atients with cardiovascular disease, including those with
HF (4), are a population at substantial risk for
steoporotic-related fractures (10–12). Spironolactone is
ncreasingly being used to treat hypertension and CHF (13),
articularly diastolic dysfunction (14). In this large,
eterans-based study of men with CHF, long-term use of
pironolactone (6 months) was inversely associated with
otal incident fractures.
On a population basis in the U.S., fractures other than
he hip/pelvis, vertebrae, and wrist account for approxi-
ately one-third of all incident fractures and 14% of all
ost expenditures (15). In our study, spironolactone use
as inversely associated with the category of other
ractures, but not with hip fractures. Particularly in men,
ip fractures are associated with substantial mortality
16). This lack of association of spironolactone with hip
ractures may be because hip fracture prevention from
rugs used to treat osteoporosis requires long-term use
17,18). Alternatively, most hip fractures result from a
all (19), and spironolactone may not be associated with
all risk. Even at the low doses of spironolactone used in
ur study (mean dose 25 mg/day), there was an inverse
ssociation with fractures. This has important therapeutic
mplications because in clinical practice, low rather than
igh doses of spironolactone are more commonly pre-
cribed (20,21).
There are several potential mechanisms that may explain
ur findings. Spironolactone antagonizes aldosterone recep-
or binding, and aldosteronism in rats is associated with
one loss and a reduction in bone strength to flexor stress
elationship of Use of Spironolactone to Fractures (vs. Nonuse)
Table 3 Relationship of Use of Spironolactone to Fractures (vs
Fracture
Site Cases
Control
Subjects
Crude Odds
(95% CI
Total 167 668 0.480 (0.308–
Hip 36 144 0.547 (0.218–
Wrist 10 40 1.126 (0.249–
Vertebral 69 276 0.438 (0.213–
Other 52 208 0.381 (0.162–
Adjusted for smoking, body mass index, prevalent fracture, and medication exposures.
CI  confidence interval.
Relationship of Duration of Use of Spironolacton
Table 4 Relationship of Duration of Use of S
Duration of
Spironolactone Use
Crude Odds Ratio
(95% CI)
6 months (n  71) 0.406 (0.189–0.876)
6 months (n  156) 0.513 (0.311–0.847)*Adjusted for smoking, body mass index, prevalent fracture, and medication
CI  confidence interval.hat can be rescued by this drug (5,22). In addition,
pironolactone may decrease calcium and magnesium excre-
ion and increase potassium (5,13,14); these may have
mportant skeletal implications (23,24).
tudy limitations. There are several limitations to our study.
ur results are retrospective, and are confined to men, to a
ingle VAMC, and to one aldosterone antagonist. The number
f hip, vertebral, and wrist fractures was small, and the study
ay have been underpowered to detect an association of
pironolactone with site-specific fractures. Testosterone levels
ere not uniformly available. This may be particularly impor-
ant because spironolactone has antiandrogenic properties (25).
e did not have uniform data on renal or vitamin D
nsufficiency or other comorbidities, all of which are associated
ith fracture risk (26–28). Similarly, we did not have infor-
ation on calcium intake or alcohol use, which are important
eterminants of fracture risk (29,30). We did not include use of
arfarin or statins in our analyses; these medications have been
ssociated with fracture risk in some (31,32), but not all
33,34), studies. Finally, some veterans may have received care
or fractures outside of the Veterans Affairs medical system. In
ummary, because of these limitations, it is entirely possible
hat the inverse association of spironolactone use with fractures
n this population is not from the drug per se, but simply
eflects that a more robust, less frail, population was prescribed
his drug.
Our study has several unique strengths. The individual
hart review by a trained physician abstractor allowed us to
apture many more fractures, including those treated out-
ide of our VAMC, than we would have identified by
omputer-generated identification using ICD-9 codes
lone. Most importantly, this is the first, to our knowledge,
etermination of the association between spironolactone
nd fractures and is an example of research bridging “the
ench to the bedside.”
use)
p Value
Adjusted Odds Ratio
(95% CI)* p Value
) 0.0012 0.575 (0.346–0.955) 0.0324
) 0.1998 0.848 (0.255–2.825) 0.7889
) 0.8774 — —
) 0.0251 0.581 (0.252–1.343) 0.2041
) 0.0272 0.236 (0.077–0.726) 0.0118
Total Fractures (vs. Nonuse)
olactone to Total Fractures (vs. Nonuse)
p Value
Adjusted Odds Ratio
(95% CI)* p Value
0.0216 0.633 (0.276–1.447) 0.2781
0.0090 0.555 (0.313–0.981) 0.0428. Non
Ratio
)
0.749
1.375
5.105
0.902
0.897e to
pironexposures.
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n conclusion, there is an inverse association between
pironolactone use and total fractures in men with CHF.
urther studies, including randomized clinical trials of
pironolactone use with bone mineral density and fracture
nd points in men and women with CHF, should be
onsidered.
eprint requests and correspondence: Dr. Karl T. Weber,
niversity of Tennessee Health Science Center, Division of
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